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Safety of Neoral conversion in maintenance renal transplant CsA in water produces slow, variable absorption and
patients: A one-year, double-blind study. creates difficulty in monitoring the therapy to protect
Background. Despite the improved pharmacokinetic char- against the risks of toxicity and excessive or inadequateacteristics of Neoral, some centers have encountered difficulty
immunosuppression [3]. The new formulation of CsA,with the conversion of some patients from Sandimmune to
Neoralt (Novartis Pharmaceuticals, East Hanover, NJ,Neoral and have reported precipitation of toxicity and rejection.
Methods. We conducted a randomized, double-blind, paral- USA), is miscible in water and forms a microemulsion
lel-group, multicenter prospective study of stable maintenance in the gut. The Neoral formulation has a bioavailability
renal transplant patients to compare the safety and tolerability
that is approximately 30% greater than that of Sandim-of converting from Sandimmune to Neoral (N 5 132) versus
mune and, perhaps more importantly, is absorbed muchcontinuing Sandimmune (N 5 130). Patients were studied for
one year. The cyclosporine (CsA) dose was adjusted as neces- more consistently within an individual [4–9]. Addition-
sary to maintain site-specific trough whole blood levels. ally, there is less effect of food, particularly fatty food,
Results. During the study, dose adjustments were frequent on absorption and blood levels of CsA, which makesin both groups: 67% Neoral versus 65% Sandimmune patients.
administration and monitoring more convenient [10, 11].At study completion, the mean trough CsA levels were compa-
Despite the improved pharmacokinetic characteristicsrable; the dose change-from-baseline did not differ statistically
between groups. Fewer Neoral (87.1%) than Sandimmune of Neoral, some centers have encountered difficulty with
(95.4%) patients reported adverse events, and serious adverse the conversion of some patients from Sandimmune to
events were comparable. Adverse events related to CsA were Neoral and have reported precipitation of toxicity andnot more common in the Neoral group. Renal function mea-
rejection [12, 13]. Other investigators, however, havesures also implied comparability of the two treatments. Three
Neoral versus five Sandimmune patients experienced acute found that individualized dose adjustments can amelio-
rejection; two Neoral versus five Sandimmune patients experi- rate toxicity without increasing the risk of rejection
enced chronic graft dysfunction. Two septic deaths occurred [14–19]. The results of a recent open-label, single-center,
in the Neoral group. No grafts were lost.
single-arm study in the United States in maintenanceConclusions. With careful monitoring, conversion of main-
renal transplant patients converted from Sandimmunetenance renal transplant patients to Neoral can be safely accom-
plished. to Neoral [19] imply that individualized monitoring after
conversion is important. In that study, patients were con-
verted to Neoral on a mg-for-mg dose basis and the
The benefits of immunosuppression with cyclosporine dose titrated, as necessary, to re-establish each patient’s
(CsA) can be accompanied by troublesome adverse ef- prestudy trough level. More patients who received Sand-
fects, including nephrotoxicity, hypertension, and neuro- immune at a dose $4.0 mg/kg/day required a dose reduc-
toxicity [1, 2]. The lipophilic molecular structure and tion, compared with those whose Sandimmune dose was
resulting insolubility of the Sandimmune formulation of #4.0 mg/kg/day (98.6% vs. 79.6%, respectively).
A recent open-label, multicenter study in Canada has
demonstrated the safety and efficacy of conversion inKey words: transplantation, immunosuppression, nephrotoxicity, cyclo-
sporine A. more than 600 maintenance renal transplant recipients
[18]. This study demonstrated equivalent safety and tol-Received for publication September 14, 1998
erability of Neoral to Sandimmune and decreased phar-and in revised form January 29, 1999
Accepted for publication March 4, 1999 macokinetic variability. However, whether the results of
the Canadian study are applicable to the more heteroge- 1999 by the International Society of Nephrology
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Table 1. Inclusion and exclusion criteria for study entry Safety
Criteria Clinical safety and adverse events (AEs) were assessed
on day 3 and thereafter according to the study visit sched-Inclusion
Age: 18–65 years ule outlined earlier in this article for the monitoring
At least 6 months post-transplant of trough levels. AEs known to be associated with theReceiving Sandimmune BID for 6 months
administration of CsA, including headache, tremor, newStable serum creatinine levels for 1 montha
Stable laboratory values and physical condition for 2 months or worsening hypertension, hirsutism, gingival hyperpla-
Exclusion sia, diabetes mellitus, an increase in serum creatinine,Rejection episode within 6 months
cholesterol, or triglyceride level, hyperkalemia, or hypo-Undergoing steroid taper following rejection episode
Received dual organ transplant magnesemia, received detailed review. All AEs were
Significant coexisting diseaseb classified as mild, moderate, or severe. All rejection epi-Metastatic renal cancer or primary nonrenal cancerc
sodes were confirmed by renal biopsy and were classifiedHIV positive
Received nephrotoxic drugs, drugs known to alter CsA metabolism, as mild, moderate, or severe using the Banff (1993) diag-
or experimental therapy within 30 days nostic criteria.Received any monoclonal antilymphocyte antibody within 6 months
Scheduled laboratory evaluations were performed atSandimmune dose ,2 mg/kg/day or .10 mg/kg/day
baseline and at each study visit starting with week 1. Thea Level at entry # 2.5 mg/dl
b Bilirubin $ 2.0 mg/dl, transaminases $ 2 3 ULN if liver disease present evaluations included a complete blood cell count and
c Other than excised squamous or basal cell skin cancer
chemistry screening (serum creatinine, blood urea nitro-
gen, serum calcium, phosphorous, sodium chloride, po-
tassium, bicarbonate, alanine transaminase, aspartate
neous U.S. population of maintenance renal transplant transaminase, magnesium, alkaline phosphatase, albu-
patients is unclear. This article reports a randomized, min, cholesterol, triglycerides, glucose, and uric acid).
double-blind, multicenter U.S. study comparing the safety
and tolerability of Neoral to that of Sandimmune. Glomerular filtration rate evaluations and
pharmacokinetic profiling
An assessment of GFR was performed at one centerMETHODS
on a subset of 28 patients at weeks 21, 4, 24, and 52Study design and primary objective
using the Renalyzer iohexol method. Results from the
The study was a double-blind, parallel-group, random- pharmacokinetic profiling, which was undertaken on a
ized, 19-center study of the safety and tolerability of further subset of patients at two other centers, have been
the conversion of maintenance renal transplant patients reported elsewhere [20] and will not be delineated in
from Sandimmune to Neoral with one year of follow-up. this article.
Patients administered Sandimmune soft gel caps twice
daily were randomized either to continue on Sandim- Statistics
mune (N 5 130) or to convert to Neoral soft gel caps Data analyses were carried out using PC SAS (version
(N 5 132) twice daily. Pharmacokinetic profiles were
6.12; SAS Institute, Cary, NC, USA). Differences in
carried out on a subset of patients at two centers, and
characteristics and outcomes of patients were tested us-the glomerular filtration rate (GFR) evaluations were
ing Fisher’s exact test (two-tailed) for categorical vari-performed on a second subset of patients at a third
ables, and, for continuous variables, either the Wilcoxoncenter.
rank sums test or, for demographic variables, analysis
of variance. Differences with probabilities # 0.05 wereStudy population, randomization, and
considered significant. For descriptive purposes, quantita-study medication
tive variables are typically reported using the mean (6sd).The key inclusion and exclusion criteria are detailed
in Table 1. Study medications, provided by Novartis
Pharmaceuticals Corporation, were identical in appear- RESULTS
ance and odor. Dosing of the study medication was ad-
Baseline demographic characteristicsjusted to maintain center-specific target CsA whole blood
Baseline demographic characteristics were compara-trough levels. CsA blood levels were determined by a
ble for the two groups and were representative of thecentral laboratory (Clinical Reference Laboratory, Len-
general population of renal transplant recipients in theexa, KS, USA) using the Abbot monoclonal TDxt assay.
United States (Table 2). Overall, the mean age at ran-Blood levels were measured at the following times during
domization was 42.6 years. Fifty-five percent were male,the study: weeks 22, 21, days 0 (day of conversion) and
and 74% were white. The mean time from transplanta-3, weeks 1 and 2, months 1, 2, 3, 4, 5, 6, and 9, and at
the study completion. tion to conversion was 40.4 months. The frequency distri-
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Table 2. Baseline demographic characteristics at randomization study drug, whereas that of the second was not. No renal
allografts were lost during the study.Neoral Sandimmune
Patient characteristics (N 5 132) (N 5 130)
Acute rejection and chronic graft dysfunction
Age yearsa 43.8611.1 41.4 611.5
Gender N (%) Acute rejection occurred in eight (3.1%) patients dur-
Male 74 (56.1) 70 (53.8) ing the course of the study. Three patients in the Neoral
Female 58 (43.9) 60 (46.2)
group (2.3%) experienced a total of four rejection epi-Race N (%)
White 94 (71.2) 101 (77.7) sodes. Five patients (3.8%) in the Sandimmune group
Black 25 (18.9) 14 (10.8) experienced a total of five episodes. All rejections were
Other 13 (9.9) 15 (11.5)
of moderate severity. Chronic graft dysfunction was diag-Weighta kg 79.7619.6 76.0 616.6
Months from transplantationa 41.1625.9 39.7 627.2 nosed in two patients receiving Neoral and in five pa-
Cause of ESRD N (%) tients receiving Sandimmune. One patient in each group
Diabetes 36 (27) 32 (25)
had both acute rejection and chronic graft dysfunction.Glomerulonephritis 29 (22) 23 (18)
Hypertension 19 (14) 17 (13)
PCKD 13 (10) 15 (12) CsA dosing and levels
Other 35 (27) 43 (33)
At baseline, the mean daily CsA doses for the twoType of transplant N (%)
CRA 108 (82) 97 (75) groups were comparable (Neoral, 302 6 92 mg, 4.0 6 1.4
LD 24 (18) 33 (25) mg/kg; Sandimmune, 307 6 102 mg, 4.2 6 1.6 mg/kg).
Diabetesb N (%) 39 (30) 36 (28)
Baseline whole blood trough CsA levels were also com-Hypertension N (%) 116 (88) 114 (88)
Serum creatininea mg/dl 1.660.4 1.6 60.4 parable (Neoral, 197 6 69 ng/dl; Sandimmune, 210 6 100
Abbreviations are: ESRD, end-stage renal disease; CRA, cadaveric renal allo- ng/dl; Fig. 2). Dose adjustments were made frequently
graft; LD, living donor. throughout this double-blind study: 89 patients (67%)a Mean 6 standard deviation
b Insulin-dependent diabetes mellitus versus 84 (65%) in the Neoral and Sandimmune treat-
ment groups, respectively, experienced dose adjustment.
At study completion, the dose of CsA relative to base-
line for the Neoral group was higher in 7 (5.7%), lower
bution of the time since transplantation for each group in 65 (53.3%), and unchanged in 50 (41.0%) patients,
is shown in Figure 1. Diabetes was the most common whereas the mean daily dose decreased by 38.5 mg (0.52
specific cause of end-stage renal disease, occurring in mg/kg). For the Sandimmune group, the dose at study
26% of randomized patients. Seventy-eight percent of completion was higher in 14 (11.5%), lower in 52
the patients were recipients of a cadaveric renal allograft. (42.6%), and unchanged in 56 (45.9%) patients, whereas
the mean dose decreased by 26.4 mg (0.36 mg/kg). TheAt randomization, 30% of the Neoral patients and 28%
differences in the change from baseline between the twoof the Sandimmune patients were insulin-dependent dia-
treatment groups failed to attain statistical significancebetics, and 88% in each group were hypertensive; the
(P 5 0.07). At study completion, the means of the troughmean serum creatinine for each group was 1.6 mg/dl.
CsA levels for the two groups were also comparable:
194 6 71 ng/dl in the Neoral patients versus 189 6 67Discontinuations
ng/dl in the Sandimmune patients, and the change fromEighteen patients (10 Neoral and 8 Sandimmune) dis-
baseline was comparable for the two groups. Because thecontinued. The discontinuations related to AEs were as
weights of these maintenance-phase patients remainedfollows: for the Neoral group, death (N 5 2), rejection
essentially stable throughout the study [mean (sd)(2), cerebrovascular accident (1), and increased liver en-
change from baseline was 20.1 (64.9) and 20.3 (65.4)zymes (1); and for the Sandimmune group, the AEs were
kg for the Neoral and Sandimmune groups, respectively],
acute rejection (2), transplant nephropathy (1), and an
changes in CsA dose during the study would not be
unspecified AE (1). meaningfully affected if the dose were expressed as mg/kg.
Patient and graft survival Adverse events
Two patients in the Neoral group died of sepsis during Adverse events were reported in fewer patients ran-
the course of the study. One had been hospitalized with domized to receive Neoral (115/132, 87.1%) versus San-
symptoms of infection since week 2 of the study and had dimmune (124/130, 95.4%, P 5 0.03). There were no
received study medication for 102 days at the time of statistically significant differences between the groups in
death. The second patient developed a rapidly progres- reported AEs for any specific body system. Interestingly,
sive systemic infection after receiving study medication there were also no significant differences in AEs that
for 200 days. In the opinion of the investigators, the are known to be CsA related (Table 3). This observation
is important because the higher CsA exposure affordeddeath of the first patient was possibly related to the
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Fig. 1. Frequency distribution of time since
transplantation for the Neoral (j) and Sand-
immune (h) treatment groups.
Fig. 2. Mean (6 SD) whole blood trough
cyclosporine levels (ng/ml) in patients treated
with Neoral (solid line) or Sandimmune
(dashed line) over a one-year period.
by the Neoral formulation might have been thought to Glomerular filtration rate and serum creatinine levels
be associated with an increase in such AEs. At baseline, the mean GFRs were 47.9 6 16.9 ml/min/
There were no significant differences between the 1.73 m2 versus 51.6 6 15.7 ml/min/1.73 m2 in Neoral and
groups in the numbers of patients experiencing serious Sandimmune patients, respectively. The changes from
AEs. Infections occurred in 12 (9.0%) patients random- baseline over the course of the study were not statistically
ized to Neoral and in 7 (5.4%) patients randomized to significant. At study completion, the mean GFR in the
Sandimmune. Malignancy occurred in 10 (3.8%) patients two groups had decreased by 2.5% (46.7 6 22.0 ml/min/
overall; renal cell carcinoma occurred in one patient 1.73 m2) for the Neoral patients versus 2.3% (50.4 6 14.8
receiving Neoral, and squamous cell carcinoma occurred ml/min/1.73 m2) for the Sandimmune patients.
in two patients who received Neoral and four patients Throughout the study, renal function, as assessed by
who received Sandimmune. Basal cell carcinoma oc- serum creatinine levels, remained stable in the majority
curred in two patients who received Neoral and three of patients in both treatment groups. Four patients in
the Neoral group and three patients in the Sandimmunepatients who received Sandimmune.
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Table 3. Number of patients with adverse events possibly related in the Neoral group and 21 (16.2%) in the Sandimmune
to cyclosporinea group.
Neoral Sandimmune
Laboratory evaluations
Event N (%)
Except where noted in Table 3, no differences wereHeadache 23 (17.4) 21 (16.2)
observed in laboratory values when comparing the Neo-Tremors 7 (5.3) 5 (3.9)
Hypertension 19 (14.4) 20 (15.4) ral and Sandimmune treatment groups.
Hirsutism 1 (0.8) 4 (3)
Gingival hyperplasia 11 (8.3) 16 (12.3) Subgroup analysesDiabetes (worsening) 0 1 (0.8)
Elevated cholesterol 12 (9.0) 13 (10.0) It has been suggested that certain subgroups of pa-
Elevated triglycerides tients (for example, blacks and diabetics) might differat any timeb 69 (52.3) 43 (33.3)c
with regard to absorption of CsA. This study was notat study completion 32 (27.4) 21 (17.4)
Hyperkalemia 1 (0.9) 1 (1.0) designed to assess the effects of these subgroups conclu-
Hyperbilirubinemia 13 (9.8) 19 (14.7) sively. Although the patient population sampled for this
a Because of missing observations, Neoral and Sandimmune sample sizes vary study might be considered representative of the U.S.slightly among events
b The Neoral group had a statistically greater mean triglyceride level at baseline renal transplant population, the relatively small number
c P 5 0.003 of black patients preclude meaningful analysis of racial
differences. With regard to patients with insulin-depen-
dent diabetes mellitus (IDDM), examination of variables
directly related to CsA absorption, that is, CsA dose,Table 4. Number of patients with 20% or 30% increase from
baseline (1) in creatinine intent-to-treat population trough, and creatinine levels, revealed that the compari-
son between Neoral and Sandimmune did not differ forWith 20% increase With 30% increase
Total the IDDM versus non-IDDM subgroups (P . 0.10). The
Visit and treatment N N (%)
number of clinically meaningful AEs that occurred in
Week 1 the diabetic patients in this study, for example, deathsNeoral 123 11 (8.9) 3 (2.4)
and rejection episodes, were too few to address the po-Sandimmune 121 7 (5.8) 2 (1.7)
Week 2 tential influence of diabetic status.
Neoral 129 7 (5.4) 3 (2.3)
Sandimmune 127 7 (5.5) 2 (1.6)
Week 4 DISCUSSIONNeoral 131 9 (6.9) 6 (4.6)
Sandimmune 127 7 (5.5) 3 (2.4) The purpose of this study was to compare the safety
Week 8 and tolerability of Neoral with Sandimmune in the het-Neoral 130 13 (10.0) 5 (3.8)
erogeneous U.S. population of stable, maintenance, re-Sandimmune 127 13 (10.2) 5 (3.9)
Week 16 nal transplant patients. The results showed that not only
Neoral 124 15 (12.1) 7 (5.6)
was Neoral as safe and well tolerated as Sandimmune,Sandimmune 116 16 (13.8) 6 (5.2)
Week 24 but with the careful monitoring mandated in this double-
Neoral 127 23 (18.1) 10 (7.9) blind study, there were fewer AEs associated with con-
Sandimmune 124 24 (19.4) 10 (8.1)
verting to Neoral compared with remaining on Sandim-Week 36
Neoral 125 18 (14.4) 10 (8.0) mune. Importantly, AEs typically associated with CsA
Sandimmune 122 19 (15.6) 7 (5.7) were not observed any more frequently in the Neoral
Study completion
treatment group, despite the presumed higher area underNeoral 119 15 (12.6) 5 (4.2)
Sandimmune 122 23 (18.9) 7 (5.7) the curve (AUC) and maximum concentration (Cmax)
implied by the results of previous studies [20, 21]. The
number of patients with at least one notable (more than
30% over baseline) increase in creatinine in this double-
group had notably elevated creatinine levels (.30%) blind study was comparable to that seen in a recent one-
compared with baseline levels for at least three months year, open-label, single-arm study [19] that employed a
during the study. At study completion, five Neoral pa- similar patient monitoring scheme. A comparison of
tients (4.2%) and seven Sandimmune patients (5.7%) these two conversion studies suggests that favorable out-
had serum creatinine levels of more than 30% above comes for creatinine can be achieved with close monitor-
baseline values (Table 4); of these 11 patients, 3 were ing, especially during the first four weeks after conver-
reported as experiencing chronic graft dysfunction, all sion.
in the Sandimmune group. The number of patients with Although the acute rejection and chronic graft dys-
creatinine levels of more than 30% above baseline at function rates were low in both groups, chronic graft
dysfunction did appear less often in patients converted toany scheduled visit throughout the study was 28 (21.2%)
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S: Cyclosporine-induced hypertension and decline in renal functionNeoral than in those continuing on Sandimmune, despite
in healthy volunteers. J Hypertens 15:319–326, 1997
the relatively short duration of the study. This observa- 3. Kahan BD: Cyclosporine. N Engl J Med 321:1725–1738, 1989
4. Kovarik JM, Mueller EA, van Bree JB, Tetzloff W, Kutztion, although not indicative of a statistically significant
K: Reduced inter- and intraindividual variability in cyclosporinedifference between treatments, is consistent with the sug-
pharmacokinetics from a microemulsion formulation. J Pharm Sci
gestion that the improved pharmacokinetics offered by 83:444–446, 1994
5. Holt DW, Mueller EA, Kovarik JM, van Bree JB, Kutz K:Neoral [20], highlighted by greatly reduced intrapatient
The pharmacokinetics of Sandimmune Neoral: A new oral formu-variability, may be related to improved clinical out-
lation of cyclosporine. Transplant Proc 26:2935–2939, 1994
comes. Although no studies have been published that 6. Mueller EA, Kovarik JM, van Bree JB, Tetzloff W, Grevel J,
Kutz K: Improved dose linearity of cyclosporine pharmaokineticscorrelate long-term graft survival with the marked im-
from a microemulsion formulation. Pharm Res 11:301–304, 1994provement in CsA pharmacokinetics available with Neo-
7. Wahlberg J, Wilczek HE, Fauchald P, Nordal KP, Heaf JG,
ral, Kahan et al, using multivariate analyses of data from Olgaard K, Hansen JM, Lokkegaard H, Mueller EA, Kovarik
JM: Consistent absorption of cyclosporine from a microemulsion204 stable renal transplant patients treated for up to five
formulation assessed in stable renal transplant recipients over ayears with Sandimmune, estimated that 27% of the risk
one-year study period. Transplantation 60:648–652, 1995
of chronic graft dysfunction was attributable to a greater 8. Kovarik JM, Mueller EA, van Bree JB, Fluckinger SS, Lange
H, Schmidt B, Boesken WH, Lison AE, Kutz K: Cyclosporinethan 20% intrapatient variability of the dose-corrected
pharmaokinetics and variability from a microemulsion formula-average blood CsA level [22]. Additionally, Senel et al
tion: A multicenter investigation in kidney transplant patients.
have shown an improvement in one-year rejection-free Transplantation 58:658–663, 1994
9. Kovarik JM, Mueller EA, Richard F, Niese D, Halloran PF,allograft survival of 61% with Neoral versus 43% with
Jeffery J, Paul LC, Keown PA: Evidence for earlier stabilizationSandimmune in 143 de novo renal transplant recipients
of cyclosporine pharmacokinetics in de novo renal transplant pa-
[15]. Reduced intrapatient variability of key pharmacoki- tients receiving a microemulsion formulation. Transplantation 62:
759–763, 1996netic parameters, AUC and Cmax, upon conversion to
10. Mueller EA, Kovarik JM, van Bree JB, Grevel J, Lucker PW,Neoral, was previously established [20] and was con-
Kutz K: Influence of a fat-rich meal on the pharmacokinetics of
firmed by a recent study of 66 maintenance renal trans- a new oral formulation of cyclosporine in a crossover comparison
with the market formulation. Pharm Res 11:151–155, 1994plant patients converted from Sandimmune to Neoral [21].
11. Kahan BD, Dunn J, Fitts C, Van Buren D, Womboldt D, PollakIt is important to emphasize that this study was a
R, Carson R, Alexander JW, Choc M, Wong R, Hwang DS:
double-blind study performed in a heterogeneous U.S. Reduced inter- and intrasubject variability in cyclosporine pharma-
cokinetics in renal transplant recipients treated with a microemul-population that broadly confirms the clinical and phar-
sion formulation in conjunction with fasting, low-fat meals, or high-macokinetic findings of an earlier multicenter open-label
fat meals. Transplantation 59:505–511, 1995
Canadian study [18]. Taken together, these studies sug- 12. Bennett WM, DeMattos A, Norman DJ, Meyer MM, Olyaei A:
Which cyclosporin formulation? Lancet 348:205, 1996gest that the conversion of stable renal transplant recipi-
13. Filler G, Ehrich J: Which cyclosporine formulation? Lancet 348:ents from Sandimmune to Neoral is safe and well toler-
1176–1177, 1996
ated when monitored closely. 14. Kovarik JM, Kallay Z, Mueller EA, van Bree JB, Arns W,
Renner E: Acute effect of cyclosporine on renal function following
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